Baudax Bio Performance
| BXRXDelisted Stock | USD 0.76 0.06 7.32% |
The firm shows a Beta (market volatility) of 2.95, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Baudax Bio will likely underperform. Baudax Bio right now shows a risk of 0.0%. Please confirm Baudax Bio treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Baudax Bio will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Baudax Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Baudax Bio is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 5.6 M |
Baudax |
Baudax Bio Relative Risk vs. Return Landscape
If you would invest 76.00 in Baudax Bio on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Baudax Bio or generate 0.0% return on investment over 90 days. Baudax Bio is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Baudax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Baudax Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Baudax Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Baudax Bio, and traders can use it to determine the average amount a Baudax Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BXRX |
Based on monthly moving average Baudax Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Baudax Bio by adding Baudax Bio to a well-diversified portfolio.
Baudax Bio Fundamentals Growth
Baudax Stock prices reflect investors' perceptions of the future prospects and financial health of Baudax Bio, and Baudax Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Baudax Stock performance.
| Return On Equity | -47.04 | |||
| Return On Asset | -1.15 | |||
| Operating Margin | (27.60) % | |||
| Current Valuation | 17.72 M | |||
| Shares Outstanding | 43.59 M | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 0.75 X | |||
| Revenue | 1.27 M | |||
| EBITDA | (34.76 M) | |||
| Cash And Equivalents | 5.65 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 7.12 M | |||
| Debt To Equity | 2.26 % | |||
| Book Value Per Share | (0.84) X | |||
| Cash Flow From Operations | (14.31 M) | |||
| Earnings Per Share | (94.13) X | |||
| Total Asset | 10.03 M | |||
| Retained Earnings | (190.9 M) | |||
| Current Asset | 21.72 M | |||
| Current Liabilities | 7.92 M | |||
About Baudax Bio Performance
Evaluating Baudax Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Baudax Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Baudax Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. Baudax Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 80 people.Things to note about Baudax Bio performance evaluation
Checking the ongoing alerts about Baudax Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Baudax Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Baudax Bio is not yet fully synchronised with the market data | |
| Baudax Bio has some characteristics of a very speculative penny stock | |
| Baudax Bio has a very high chance of going through financial distress in the upcoming years | |
| Baudax Bio currently holds 7.12 M in liabilities with Debt to Equity (D/E) ratio of 2.26, implying the company greatly relies on financing operations through barrowing. Baudax Bio has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Baudax Bio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 1.27 M. Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (5.74 M). | |
| Baudax Bio currently holds about 5.65 M in cash with (14.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
- Analyzing Baudax Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Baudax Bio's stock is overvalued or undervalued compared to its peers.
- Examining Baudax Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Baudax Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Baudax Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Baudax Bio's stock. These opinions can provide insight into Baudax Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Baudax Stock
If you are still planning to invest in Baudax Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Baudax Bio's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |